# Wellington Partners

Wellington Partners is a Private Equity based in Munich, Bavaria, Germany.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Munich, Bavaria, Germany
- **Region:** Europe
- **Address:** Türkenstraße 5, 80333 Munich, Germany
- **Founded:** 1998
- **Assets under management:** ~€800 million
- **Website:** wellington-partners.com
- **LinkedIn:** https://www.linkedin.com/company/wellington-partners
- **Wikidata:** Q1666244

## Regulatory record

- **CRD number:** 333839
- **SEC file number:** 802-132207
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/333839

## About

Wellington Partners is a leading European venture capital firm investing in early- and growth-stage life science companies. Since 1998 it has supported entrepreneurs turning breakthrough technologies into global businesses across Germany, Europe and beyond. It focuses on sectors including Therapeutics, Medical Devices, Diagnostics, Digital Health and Industrial Biotechnology.

## Sectors

- Digital Health
- Medical Devices
- Diagnostics
- Industrial Biotechnology

## Offices

- Seidengasse 16, 8001 Zurich, Switzerland

## People

- Dr. Rainer Strohmenger — Managing Partner
- Dr. Johannes Fischer — Managing Partner
- Dr. Varun Gupta — Partner
- Harald Keller — Managing Partner, CFO
- Ernst Mannheimer — Managing Partner, Legal Counsel
- Sabine Kannegiesser — Partner
- Dr. Regina Hodits — Venture Advisor

## Questions

### Does Wellington Partners invest outside of Europe?

Wellington states it focuses on companies from Germany, Europe, and beyond. Its Zurich office and portfolio companies like Polares Medical, which is U.S.-focused, indicate the firm will back European-origin companies that pursue global regulatory pathways, including FDA approval in the United States.

### How is Wellington Partners' current fund different from its predecessors?

WPLS V, the firm's fifth fund, closed at EUR 210 million, which the firm reports is more than double the volume of its predecessor. It was considerably oversubscribed and remains focused on biotechnology and medical technology.

## Related profiles

- [Wealth Harbour Investment](https://altss.com/profile/wealth-harbour-investment)
- [WestBridge Capital](https://altss.com/profile/westbridge-capital-partners)

---

Last updated: 2026-08-11T15:08:32.892Z

Canonical page: https://altss.com/profile/wellington-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology